VistaGen Therapeutics, Inc. (VSTA) Vision for Stem Cell Technology Aligned with Broader Hopes for Cardiotoxicity
The U.S. pharmaceutical industry is facing a “drug discovery and development crisis,” says small-cap biotech VistaGen Therapeutics, evidenced by the fact that while the pharmaceutical industry in 2012 invested nearly $49 billion in R&D, a total of only 39 novel drugs were approved by the FDA. The hang-up is on the costly price tag of drug development and non-approval due to safety concerns of the candidates. In recognition of this crisis, a movement toward the use of stem cell technology to address these issues has begun. VistaGen is already on board, leveraging its human cells derived from its human pluripotent…